[New - direct oral anticoagulants: actual review]. / Nová - prímá perorální antikoagulancia: aktuální prehled.

ABSTRACT

In recent years the options of anticoagulant/antithrombotic therapy have extended with new - direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards "the ideal antithrombotic drug", and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.Key words apixaban - dabigatran - DOAC - NOAC - rivaroxaban.